Gilead Will Urge Blood Monitoring For Adefovir-Associated Nephrotoxicity
Executive Summary
Gilead will recommend that adefovir dipivoxil labeling advise blood monitoring to assess nephrotoxicity if the nucleoside reverse transcriptase inhibitor is approved, Gilead Senior VP Mark Perry told analysts at a conference sponsored by Warburg Dillon Reed September 30 in New York City.